Supplemental Material

Covariate Condition	Inclusive conditions	Definition*
Malignancy	Cancer excluding non	ICD 9- CM diagnosis codes:140 X-208 X (exclude 173)
	melanoma skin cancer	
Liver/ Respiratory failure	1 End stage liver disease	ICD 9- CM diagnosis codes: 570 X- 573 X
	2 Respiratory failure	ICD 9 CM diagnosis codes: 518.81 518.83 518.84 799.1 415.X 416.X
Congestive Heart Failure	CHE (excluding post	ICD 9 CM diagnosis codes: 128 X 402 01 402 11 402 01 404 03 404 11
congestive near randre	procedure-CHE)	104 3 104 01 104 03 425 Y
Cardiovacoular disaasa		100, 10, 100, 100, 100, 100, 100, 100,
Caldiovasculai disease	2. Obstructive coronary	ICD = CM diagnosis codes: 410.X, 412.X, 423.7A
	2. Obstructive coronary	ICD 9- CM diagnosis codes: 26.01, 26.02, 26.02, 26.05, 26.00, 26.10, 26.10
	uisease	CD3-cm procedure codes: 30.01, 30.02, 30.03, 30.03, 30.09, 30.10-30.19
		CPT procedure codes. 3553-36, 33510-23, 35530, 92960-62, 92964, 92995-6, 92974
	3. TIA	ICD 9- CM diagnosis codes: 430.X
	4. Sliuke	ICD 9- CM diagnosis codes: 430.2, 431.2, 434.4, 432.5, 436.5
	5. Periprieral altery disease	ICD 9- CM diagnosis codes.440.2X, 442.2, 443.1, 443.9, 445.0X ICD9-CM procedure
		COUCES.30.00-09, 30.10, 30.30, 30.39, 30.40, 30.49, 30.00, 30.09, 39.20, 39.29, 39.3,
	amputation	04.17, 04.10-04.17
		CPT procedure codes. 35226,35256,35266,35351,35355,35377,35372,35361,
		35454, 35450, 35459, 35473, 35474, 35482, 35483, 35485, 35492, 35493, 35495,
		35546, 35546, 35549, 35551, 35556, 35556, 35563, 35563, 35560, 35571, 35563,
		35585, 35587, 35646, 35651, 35654, 35656, 35661, 35663, 35665, 35666, 35671,
		34800, 34802-5
	6. Carotid revascularization	CD9-CM procedure codes: 38.12, 38.11, 00.51, 00.53, 39.28
		UPT procedure codes: 35301, 00051, 00061, 00071, 00751, 00761, 37215, 37216
	Z Destevitelling Operated	HCPCS procedure code: S2211
	7. Pentoxitylline & related	Medications: Pentoxityiline, Cilostazol, Cyclandelate, Ethaverine HCL, Nicotinyi Alconol
Operations Manufal Illerance	arugs	Tartate, Papaverine, Tolazolin
Serious Mental Illness	1. Dementia	ICD 9- CM diagnosis codes: 290.X, 291.2, 292.82, 294.1X, 331.0-331.1X, 331.82
		Medications: Donepezii, Rivastigmine, Galantamine, Lacine, Memantine
	2. Depression,	ICD 9- CM diagnosis codes: 311, 300.4, 296.2, 296.3, V79.0
	3. Schizophrenia,	ICD 9- CM diagnosis codes: 295.X
	4. Bipolar disorder	ICD 9- CM diagnosis codes: 296.0, 296.4X, 296.5X, 296.6X, 296.7, 296.80, 296.89
	5. Post traumatic stress	ICD 9- CM diagnosis codes: 309.81
Cardiaa yalya diaaaaa	alsorder	ICD 0. CM diagnosis sodes: 204 V. 205 V. 206 V. 424 0. 424 1
Arrhythmia	1 Atrial fibrillation/fluttor	ICD 9- CM diagnosis codes: 394.7, 393.7, 390.7, 424.0, 424.1
Annyunna	2 Arrhythmic and	ICD 5- Civi diagnosis codes: 427.5X
	2. Annyunna anu	10D 9- CM diagnosis codes. $420.\Lambda$, $427.\Lambda$
Smoking		ICD 9- CM diagnosis codes: 305 1 1/15 82 989 84
emenang		Medications: Varenicline tartrate Nicotine Replacement therapy (gum_patch_lozenge)
COPD/ Asthma		ICD 9- CM diagnosis codes: 491 X 492 X 493 X 496 X 1/17 5 1/81 3
HIV		ICD 9- CM diagnosis codes: 042, 079.53, 795.71, V08
		Medications: Zidovudine, Didanosine, Zalcitabine, Stavudine, Indinavir, Ritonavir,
		Saquinavir, Nevirapine, Nerrinavir, Delavirdine, Delavirdine, Abacavir, Amprenavir,
Darking and Disease		Etavirenz, Lamivudine-Zidovudine, Ritonavir-Lopinavir, Abacavir-Lamivudine-Zidovudine
Parkinson's Disease		ICD 9- CM diagnosis codes: 332
		Medications: Apokyn, Apomorphine, Carbidopa/levodopa, Entacapone, Pergolide,
		Pramipexole, Ropinirole, Rotigotine, Selegiline, Toicapone, Zelapar, Azliect/Rasagiline,
Madiaationa		Emsam, isocarboxazio, Pheneizine, Tranyicypromine
Antinevelotice	Atypical and typical	Lithium Clazanina Halanaridal Lavanina Lurasidana Malindana Olanzanina
Antipsycholics	Atypical and typical	Dolinovidence Quetioning France Dimensional Constraints Annual Constraints, Constra
	anipsycholic medications	Chlorpromazine, Eluphenazine, Eluphenazine Deconate, Mesoridazine, Perphenazine
		Thioridazine, Thiorhivene: Trifluonerazine: Trifluonerazine Asenanine, Chlororothivene
		Incerdane, Molindone Primazine, Principalitie, materialitie, Asetaphie, Childrene, Child
ACE Inhibitors		Benazenril Cantoril Englarril Englarril Licinopril Licinopril Maevinil Periodopril Quinapril
alone/combination		Benazepini, Captopini, Enalapini, i Osinopini, Eisinopini, Moexipini, i ennuopini, Quinapini, Reminril Trendolenril
alone/combination		Ramphi, Hahuulaphi
ARBS alone/combination		Candesartan, Eprosartan, Irbesartan, Losartan, Azilsartan, Olmesartan, Telmisartan,
		Valsartan
Beta-blockers		Acebutolol, Atenolol, Betaxolol, Bisoprolol, Carteolol, Carvedilol, Esmolol, Labetalol,
		Metoprolol Tartrate, Metoprolol Succinate, Propranolol, Penbutolol, Pindolol, Nadolol,
		Sotalol, Timolol, Nebivolol
Calcium Channel Blockers		Amlodipine, Isradipine; Felodipine, Nifedipine, Nifedipine ER, Nicardipine; Diltiazem,
		Verapamil, Nimodipine; Nisoldipine; Bepridil, Amlodipine/Atorvastatin, Clevidipine
		Butyrate

Table S1. Definitions of comorbid conditions and medications, on the basis of codes and prescriptions in 730 days before treatment intensification

Thiazide diuretics/ Potassium sparing diuretics			Chlorothiazide, Chlorthalidone, Hydrochlorothiazide, Methyclothiazide, Trichlormethiazide, Metolazone, Indapamide, Eplerenone; Amiloride, Spironolactone, Triamterene, Hydrochlorothiazide/Triamterene, Hydrochlorothiazide/Spironolactone, Bendroflumethiazide, Benzthiazide, Cyclothiazide, Hydroflumethiazide, Polythiazide, Quinethazone
Other Antihypertensives			Doxazosin, Prazosin, Terazosin, Clonidine, Guanabenz, Guanfacine, Hydralazine, Methyldopa, Metyrosine, Reserpine, Minoxidil, Alfuzosin, Silodosin, Alseroxylon, Cryptenamine, Deserpidine, Diazoxide Guanethidine, Iloprost, Mecamylamine, Pargyline, Rescinnamine. Trimethabhan Camsylate
Anti-arrhythmics Digoxin	1.	Digoxin	Digoxin, Digitalis
and other inotropes	2.	Anti- Arrythmics	Adenosine, Amiodarone, Lidocaine, Flecainide, Ibutilide, , Procainamide, Propafenone, Ropafenone, Quinidine, Disopyramide, Verapamil, Dofetilide, Mexiletine, Moricizine, Tocainide
Anticoagulants and Platelet inhibitors, not aspirin	1.	Anticoagulants	Warfarin, Argatroban, Bivalirudin, Dalteparin, Enoxaprin, Eptifibatide, Fondaparinux, Heparin, Lepirudin, Tirofiban, Tinzaparin, Reviparin, Nadroparin, Ardeparin, Certoparin, Dabigatran
	2.	Platelet Inhibitors	Clopidogrel, Ticlopidine, Aspirin/Dipyridamole, Dipyridamole alone, Abciximab, Factor IX, Factor VIIa, Factor VIII, Prasugrel, Ticagrelor
Statins			Atorvastatin, Fluvastatin, Lovastatin, Pravastatin, Simvastatin, Rosuvastatin, Cerivastatin Pitavastatin, Lovastatin ER, Ezetimibe/Simvastatin, Lovastatin/Niacin, Amlodipine/Atorvastatin
Non-Statin lipid lowering drugs			Cholestyramine, Colesevelam, Clofibrate, Colestipol, Niacin, Niacinamide, Fish Oil Concentrate, Omega 3 Fatty Acids, Gemfibrozil, Fenofibrate, Fenofibric Acid, Ezetimibe Omacor, Tricor/Fenofibrate, Ezetimibe/Simvastatin
Nitrates			Amyl Nitrate, Isosorbide Dinitrate, Isosorbide Mononitrate, Erythrityl Tetranitrate, Nitroglycerin (all formsSA, Patch, SL, Ointment; Aerosol spray), Ranolazine
Aspirin			Aspirin, Aspirin/ Dipyridamole
Loop Diuretics			Furosemide, Ethacrynic acid, Bumetanide, Torsemide

ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; COPD = chronic obstructive pulmonary disease; CPT = Current Procedural Terminology; ICD-9- CM = International Classification of Diseases, Ninth Revision; MI = myocardial infarction; TIA = transient ischemic attack If medications are combinations of 2 drug classes then a patient is recorded as using both medications. * Each co-morbid condition was defined as present if there was 1 specified inpatient or 2 specified outpatient codes separated by 30 days, or 1 specified procedure code or prescription for a medication defining that comorbid condition in the 730 days before treatment intensification.

Table S2. Details for the construction of the propensity score model

The pre-matching cohort was composed of all eligible persons who initiated metformin or sulfonylurea for diabetes and met the study's inclusion criteria. The matched cohort was formed by matching metformin users to sulfonylurea users with similar propensity scores. The propensity score (PS) is defined as the probability of sulfonylurea use, given a particular pattern of baseline covariates (Table 2). We estimated the PS using a logistic regression model in which the dependent variable was 1 for patients who used sulfonylurea and 0 for metformin users and used restricted cubic splines (3 knots) for continuous covariates in the model. The PS model is designed to be non-parsimonious and highly flexible to capture all observable confounding by indication. Indicator variables denoting missingness were included in the PS model, allowing the PS to balance missingness patterns between the exposures and control for potentially informative missingness. Multiply imputed PS model coefficients were aggregated using Rubin's rules and the aggregated model used to generate PS values. The PS model is displayed in Appendix Table 2. The PS model yielded a C statistic of 0.71. When used to facilitate matching, the success of the PS model is determined by the covariate balance achieved in the matched cohort. Table S1 and Figures S2 and S3 demonstrate the mean standardized differences before and after propensity score matching. Indicating good balance after matching, all standardized differences have an absolute value < 0.1. An important condition for propensity score methods is that every cohort member have a nontrivial probability of having received either of the study therapies (positivity). Our matching procedure excluded sulfonylurea patients for whom very few similar metformin users existed. Unmatched sulfonylurea patients primarily were older, had higher number of co-morbidities and had a higher serum creatinine at the time of drug initiation (See Table S3 for characteristics of unmatched patients). The matching was performed on the log odds of the propensity scores using an 8:1 digit greedy match algorithm.

Characteristic	Odds Ratio		vals
Comorbidities			
Malignancy	1.06	1.02	1.11
Liver/ respiratory failure	2.12	1.94	2.31
Congestive heart failure	1.60	1.53	1.67
Cardiovascular disease	1.02	0.99	1.04
Serious mental illness	0.98	0.95	1.01
Cardiac valve disease	1.04	0.96	1.12
Arrhythmia	1.02	0.98	1.06
Smoking	1.01	0.98	1.05
Chronic Obstructive Pulmonary Disease/ Asthma	1.01	0.98	1.05
HIV	1.66	1.45	1.91
Parkinsons	1.02	0.90	1.15
Indicators of health care utilization			
Hospitalized in last year (VA)	1.12	1.07	1.18
Hospitalized in last year (Medicare)	1.05	0.98	1.12
Hospitalized in last year (Medicaid)	0.92	0.72	1.17
Hospitalized in month of incident diabetes prescription (VA)	1.12	1.05	1.20
Hospitalized in month of incident diabetes prescription			
(Medicare)	1.21	1.11	1.31
Hospitalized in month of incident diabetes prescription			
(Medicaid)	1.11	0.76	1.61
Nursing Home encounter in last year	0.90	0.61	1.33
Number of medications	1.12	1.09	1.15
Outpatient Visits in past year	1.00	0.98	1.02
Medicare encounters in last year	0.92	0.90	0.94
Medicald encounters in last year	1.11	1.05	1.17
	4.40		4.00
	1.19	1.15	1.23
Race Other	1.11	1.06	1.17
Gender Female	0.54	0.50	0.57
Age	1.35	1.32	1.39
Incluent therapy date	0.65	0.64	0.66
	4.00	4.00	
	1.09	1.08	1.11
Systolic Blood pressure	1.06	1.04	1.07

Logistic regression model for the probability of initiating Sulfonylurea (N=65,986 matches)

OFO/ Confidence

Diastolic Blood pressure	0.99	0.97	1.00
Body Mass Index	0.76	0.74	0.77
Low Density Lipoprotein	1 02	1 01	1 03
Croatining	1.02	1.01	1 15
	1.11	1.00	1.15
Estimated Glomerular Filtration Rate	0.80	0.77	0.83
Urine Protein negative	1.07	1.02	1.11
Lirine Protein Trace or 1+	1 21	1 15	1 26
	1.21	1.15	1.20
Proteinuna present at 2+,	1.26	1.17	1.36
Proteinuria present at 3+,	1.29	1.09	1.52
Proteinuria present at 4+	2 00	1 17	3 43
Modications	2:00		0.10
ACE Inhibitors	0.98	0.96	1.00
ARBs	0.92	0.89	0.96
Calcium Channel Blockers	0 99	0.97	1 02
Date Blackers	0.00	0.07	1.02
Dela Diockers	1.04	1.02	1.06
Thiazide and k sparing	0.97	0.95	0.99
Other Anti hypertensive medications	0.96	0.94	0.99
Statin lipid loworing agents	0.75	0.72	0.76
	0.75	0.73	0.76
Non-statin lipid lowering agents	0.90	0.88	0.93
Anti-arrhythmics, digoxin and inotropes	1.15	1.07	1.23
Anticoagulant	1.05	1 01	1 10
Nitrotoo	1.00	1.01	1.10
INITATES	1.12	1.09	1.16
Aspirin	0.97	0.95	1.00
Loop Diuretics	1 44	1 40	1 40
Antinovahatiaa	1.11	1.40	1.40
Anupsycholics	1.06	1.02	1.11
Oral glucocorticoids	1.03	0.99	1.06
Indicators of Missing covariates imputed			
HbA1c missing	0.07	0.04	1 00
	0.97	0.94	1.00
LDL missing	1.08	1.05	1.11
Glomerular filtration rate missing	1.25	1.21	1.30
Blood pressure missing	0.93	0.85	1 03
Diodu pressure missing	0.00	0.00	1.00
Bivil missing	1.23	1.14	1.33
Race missing	0.92	0.87	0.96
Urine protein testing missing	0.97	0 94	0 99
Leastion of care versus station E90	0.57	0.04	0.00
Location of care versus station 569			
Station 402	0.85	0.75	0.97
Station 405	0.84	0 71	1 00
Station 426	0.00	0.77	1.00
Station 450	0.90	0.77	1.05
Station 437	1.83	1.59	2.12
Station 438	1.15	1.00	1.32
Station 442	0.72	0.58	0.89
Station 459	1 21	1.00	1 /6
Station 409	1.21	1.00	1.40
Station 460	1.00	0.87	1.16
Station 463	0.48	0.38	0.60
Station 501	0.92	0.81	1.04
Station 502	1 42	1 26	1 60
Station 502	1.20	1.10	1.00
Station 504	1.30	1.13	1.49
Station 504	1.43	1.22	1.67
Station 506	0.98	0.85	1.14
Station 508	2.30	2.05	2.57
Station 509	1 12	0.07	1 30
Station 509	1.12	0.37	1.50
Station 512	1.46	1.29	1.64
Station 515	1.16	1.00	1.34
Station 516	0.87	0.79	0.96
Station 517	1 12	0.94	1 33
Station 517	0.00	0.04	1.00
Station 518	0.90	0.73	1.10
Station 519	1.82	1.53	2.16
Station 520	0.91	0.81	1.02
Station 521	0.63	0.56	0 72
Station 522	4.00	1.00	4 40
Stati011 323	1.23	1.09	1.40
Station 526	1.04	0.88	1.25
Station 528	1.07	0.98	1.17
Station 529	2.30	1.93	2 74
Station 521	0.54	0.40	0.64
Station 504	0.51	0.42	0.01
Station 534	0.75	0.66	0.86
Station 537	1.58	1.39	1.78
Station 538	2.27	1.94	2.66
Station 539	0.70	0 60	0 02
	0.13	0.03	0.52

Ctation 540	4.00	4.00	4 45
Station 540	1.26	1.09	1.45
Station 541	0.95	0.87	1.05
Station 542	1.03	0.87	1 22
	1.05	0.07	1.22
Station 544	1.61	1.45	1.79
Station 546	1.16	1.03	1.31
Station 549	2 10	2.97	3 55
Station 546	5.19	2.07	5.55
Station 549	1.74	1.59	1.91
Station 550	1.73	1.51	1.98
Charlen 550	0.70	0.00	0.00
Station 552	0.78	0.68	0.89
Station 553	1.48	1.29	1.71
Station 554	1 37	1 22	1 55
	1.07	0.74	1.00
Station 556	0.88	0.74	1.04
Station 557	1.52	1.32	1.77
Station 558	0.89	0.78	1 01
	0.00	0.70	1.01
Station 561	1.51	1.36	1.68
Station 562	2.10	1.79	2.46
Station 564	1 20	1 07	1 36
	1.20	1.07	1.50
Station 565	1.03	0.91	1.16
Station 568	1.71	1.46	2.02
Station 570	2.01	2 55	2.22
	2.91	2.55	5.55
Station 573	1.28	1.17	1.40
Station 575	1.02	0.80	1.29
Station 579	1.25	1 1 1	1 40
Station 576	1.25	1.11	1.40
Station 580	1.25	1.14	1.38
Station 581	1.45	1.28	1.64
Station EQ2	0.80	0.70	0.00
Station 583	0.80	0.70	0.90
Station 585	1.08	0.92	1.27
Station 586	1 57	1 40	1 75
Citation 500	1.07	1.40	1.70
Station 590	1.32	1.14	1.53
Station 593	1.70	1.50	1.92
Station 595	0.87	0.77	0 99
	0.01	0.77	0.00
Station 596	0.79	0.68	0.90
Station 598	1.54	1.38	1.72
Station 600	0.80	0.70	0 92
	0.00	0.70	0.52
Station 603	1.41	1.24	1.61
Station 605	1.67	1.49	1.87
Station 607	1 02	0.88	1 17
	1.02	0.00	1.17
Station 608	0.86	0.72	1.02
Station 610	1.09	0.97	1.23
Station 612	1.05	1 76	2 17
	1.95	1.70	2.17
Station 613	1.70	1.49	1.92
Station 614	1.27	1.13	1.43
Station 618	1 24	1 1 1	1 38
	1.24	1.11	1.50
Station 619	1.67	1.47	1.90
Station 620	1.76	1.51	2.04
Station 621	0.80	0.78	1 01
	0.09	0.70	1.01
Station 623	0.83	0.72	0.94
Station 626	1.06	0.97	1.17
Station 629	1 21	1.06	1 38
	0.01	0.74	1.00
Station 630	0.81	0.71	0.93
Station 631	1.37	1.11	1.69
Station 632	0.95	0.82	1 09
	0.00	0.02	1.00
Station 635	1.39	1.24	1.55
Station 636	1.08	0.98	1.18
Station 637	0.94	0.82	1 08
	0.04	0.02	1.00
Station 640	1.02	0.91	1.16
Station 642	1.14	1.02	1.28
Station 644	1 84	1 64	2.06
Station 646	1 47	4.04	2.00
Station 040	1.47	1.31	1.65
Station 648	2.11	1.88	2.36
Station 649	1 49	1 28	1 73
	1.43	1.20	1.73
Station 050	0.66	0.56	0.77
Station 652	0.71	0.62	0.82
Station 653	1 00	0.02	1 20
	1.03	0.52	1.29
Station 654	0.72	0.61	0.86
Station 655	0.92	0.78	1.07
Station 656	0 96	0 82	1 1 2
	0.50	0.02	1.12
700 101161	1.50	1.37	1.64
Station 658	1.47	1.29	1.68
Station 659	1 61	1 1 1	1 81
	1.01	1.77	1.01

Station 660	0.59	0.51	0.69
Station 662	0.80	0.68	0.95
Station 663	1.85	1.66	2.06
Station 664	0.53	0.46	0.61
Station 666	0.85	0.66	1.09
Station 667	0.84	0.74	0.95
Station 668	1.40	1.19	1.64
Station 671	0.94	0.85	1.04
Station 672	1.62	1.47	1.79
Station 673	1.62	1.48	1.77
Station 674	0.84	0.75	0.93
Station 675	2.08	1.73	2.50
Station 676	1.18	0.99	1.39
Station 678	2.02	1.78	2.29
Station 679	1.03	0.84	1.25
Station 687	0.70	0.58	0.85
Station 688	1.46	1.29	1.65
Station 689	1.05	0.94	1.18
Station 691	1.32	1.19	1.47
Station 692	0.40	0.31	0.50
Station 693	1.57	1.39	1.76
Station 695	1.11	0.99	1.26
Station 740	0	0	infinity
Station 756	0.61	0.52	0.72
Station 757	1.71	1.48	1.97

Characteristics of patients Excluded after PS matching SufforyUrea Metomin Age, median (ICR) 77 (69, 82) 60 (55, 67) Male (%) 99 93 Race, (%) 78 78 White 78 78 Biotomic Other 17 78 Missing measurement, (%) 70 63.8.0.0 6.8.8 (52, 7.4) Missing measurement, (%) 25 17 7 Low Density Lipoprotein mg/dL, median (ICR) 93 (74, 118) 100 (80, 124) 20 Missing measurement, (%) 24 10 20 26 17 Correctinine mg/dL, median (ICR) 62 (53, 77) 87 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 22 70 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 76 (76, 100) 7	Table S3. Characteristics of patients who did not match in 1 to 1 Propensity score matching				
N=13,208 N=60,881 Age, median (IQR) 77 (89,82) G0 (55, 67) Male (%) 99 93 Bace, (%) 76 14 Hispanio Other 14 71 Hispanio Other 5 4 Main (QR) 0.7 10 Messing measurement, (%) 20 (63, 8.0) 6.8 (62, 7.4) Missing measurement, (%) 40 20 Creatinine ang/L, median (IQR) 1.2 (1.0, 1.4) 1.0 (0.8, 1.1) Gimerular filtration rate m/min, median (IQR) 2.2 (1.0, 1.4) 1.0 (0.9, 1.1) Gimerular filtration rate m/min, median (IQR) 2.4 (1.0 100 Proteinuria (%) negative 41 53 100 Missing measurement, (%) 24 10 10 Proteinuria present at 2+,	Characteristics of patients Excluded after PS matching	Sulfonylurea	Metformin		
Age, mealan (UCR) // (Ps, 62) e0 (Ps, 67) Race, (%) 78 99 93 Minite 78 76 11 White 78 76 11 Higpanic/ Other 14 11 11 Hispanic/ Other 5 14 11 Missing measurement, (%) 25 17 10 Low Density Lipoprotein mg/dL, median (IQR) 93 (74, 118) 100 (80, 124) Missing measurement, (%) 40 20 10 Creatinine mg/dL, median (IQR) 12 (10, 14) 10 (01, 03, 11) 10 Giomerular Hitzation rate mitinin, median (IQR) 24 10 10 Proteinuria, (%) negative 41 53 Urine Protein Trace or 1+ 13 8 Proteinuria, (%) negative 41 0.1 0 Missing measurement, (%) 42 33 0.9 Proteinuria, (%) proteinsure mm/Hg, median (IQR) 134 (122,150) 134 (124,144) 10 10 10 10 10 10 10 10 10 </td <td></td> <td>N=13,206</td> <td>N=60,881</td>		N=13,206	N=60,881		
mane (w) 99 95 Mace 78 76 Marce 14 11 Hispanic/Oher 5 4 Missing 0.7 10 Massing 0.7 10 Massing measurement, (%) 25 17 Cow Density Lipoprotein mydL, median (IQR) 93 (74, 118) 100 (80, 124) Massing measurement, (%) 40 20 Creatinine mydL, median (IQR) 62 (53, 77) 87 (76, 100) Gomerular filtration rate ml/min, median (IQR) 24 10 Proteinuria (%) negative 41 53 Ume Proteine Trace or 1+ 13 8 Proteinuria present 32+, 37 0.6 Vine Protein Trace or 1+ 13 8 Systolic Blood pressure mm/fg, median (IQR) 136 (122,150) 134 (124,144) Diastolic Blood pressure mm/fg, median (IQR) 27.9 (25.0, 31.2) 33.1 (29.7,37.4) Missing measurement, %) 6 2 2 Baseline Co-morbidites(%); 6 2 2		77 (69, 82)	60 (55, 67)		
Name 78 76 Black 14 11 Hispanic/ Other 5 4 Missing measurement, (%) 7.0 (6.3, 8.0) 6.8 (6.2, 7.4) Missing measurement, (%) 25 17 Low Density Lipoprotein mg/dL, median (IQR) 93 (74, 118) 100 (80, 124) Missing measurement, (%) 40 20 Creatinine mg/dL, median (IQR) 62 (53, 77) 87 (76, 100) Missing measurement, (%) 24 10 Proteinuria, %) negative 41 53 Urine Protein Trace or 1+ 13 8 Proteinuria, %) negative 41 03 Systolic Blood pressure mm/Hg, median (IQR) 138 (122,150) 134 (124,144) Diasting measurement, %) 24 3 0.9 Proteinuria, %) median (IQR) 138 (122,150) 134 (124,144) 03 Diasting measurement, %) 24 33 0.4 Diasting measurement, %) 27.9 (25, 0, 31.2) 33.1 (23.7,37.4) Basing comeronitalities %) 4 0.3 1		99	93		
Black 14 11 Hispanic/Oher 5 4 Missing measurement, (%) 7.0 (6.3, 8.0) 6.8 (6.2, 7.4) Missing measurement, (%) 25 100 (80, 124) Missing measurement, (%) 24 100 (80, 124) Creatinine mg/dL, median (IQR) 1.2 (1.0, 1.4) 1.0 (0.8, 1.1) Glomerular filtration rate ml/min, median (IQR) 24.4 10 Origonia present at a ml/min, median (IQR) 24.4 10 Froteinuria, (%) negative 44 53 Urine Proteinuria present at 3+, 0.7 0.2 Proteinuria present at 3+, 0.7 0.2 Proteinuria present at 3+, 0.7 0.2 Distolic Blood pressure mm/Hg, median (IQR) 138 (122,150) 134 (124,144) Distolic Blood pressure mm/Hg, median (IQR) 27.9 (25,0,31.2) 33.1 (22,7,37.4) Massing measurement, (%) 6 2 Bassing measurement, (%) 6 1 Distolic Blood pressure mm/Hg, median (IQR) 27.9 (25,0,31.2) 33.1 (22,7,37.4) Massing measurement, (%) 6 2	White	78	76		
Hispanic/ Missing 5 4 Missing measurement, (%) 7.0 (6.3, 8.0.) 6.8 (6.2, 7.4) Uwe Density Lipoprotein mg/cL, median (IQR) 33 (74, 118) 100 (80, 124) Missing measurement, (%) 1.2 (10, 1.4) 1.0 (0.9, 1.1) Gomerular fittration rate minim, median (IQR) 62 (53, 77) 87 (76, 100) Missing measurement, (%) 24 10 Proteinuria, (%) negative 41 13 Urine Protein Trace or 1+ 13 8 Proteinuria, (%) negative 41 10 Virine Protein Trace or 1+ 13 8 Systolic Blood pressure mm/Hg, median (IQR) 138 (122,150) 134 (124,144) Diasting measurement, (%) 42 38 Systolic Blood pressure mm/Hg, median (IQR) 138 (122,150) 134 (128,77) Missing measurement, (%) 6 2 Baseline Co-morbidities(%): 6 2 Baseline Co-morbidities(%): 9 4 1 Missing measurement, (%) 1 0.1 0.1 Congestive heart failure 279 (25,0, 31.2) <td>Black</td> <td>14</td> <td>11</td>	Black	14	11		
Missing 0.7 10 Massing measurement, (%) 70 6.3 6.0 7.7 Low Density Lipoprotein mydL, median (IQR) 93 7.4 10 90 Creatinine mydL, median (IQR) 93 7.4 10 90 7.6 10 100 10.0 10.9 1.1 10 10.9 1.1 10.0 10.9 1.1 10.0 10.9 1.1 10.0 10.9 1.1 10.0 10.9 1.1 10.0 10.9 1.1 10.0 10.9 1.1 10.0 10.9 1.1 10.0 10.9 11.1 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 11.0 10.	Hispanic/ Other	5	4		
HbA15, % median (IQR) 7.0 (6.3, 8.0) 6.8 (6.2, 7.4) Missing measurement, (%) 25 17 Low Density Lipoprotein mg/dL, median (IQR) 93 (74, 118) 100 (98, 124) Missing measurement, (%) 12 (1.0, 1.4) 10 (9.9, 1.1) Glomerular filtration rate minim, median (IQR) 62 (53, 77) 87 (76, 100) Missing measurement, (%) 24 10 Proteinuria, (%) negative 41 53 Urine Protein Trace or 1+ 13 8 Proteinuria present at 3+, 0.7 0.2 Proteinuria present at 3+, 0.7 0.2 Systolic Blood pressure mn/Hg, median (IQR) 136 (122,150) 134 (124,144) Diastic Blood pressure mn/Hg, median (IQR) 27.9 (25,0,31.2) 33.1 (29,7,37.4) Missing measurement, (%) 4 0.3 1 Baseline Co-morbidities(%); 6 1 0.1 Congestive heart failure 27 (25,0,31.2) 33.1 (29,7,37.4) 3 Malignancy 9 4 1 0.1 Cordica valve disease 11 0.3 <	Missing	0.7	10		
Missing measurement, (%) 25 17 17 Low Density Lipoprotein mydL, median (IQR) 93 (74, 118) 100 (66, 124) Missing measurement, (%) 40 20 124) Creatinian mydL, median (IQR) 1.2 (1, 0, 1.4) 1.0 (0, 9, 1.1) 10 Glomerular filtration rate m/min, median (IQR) 62 (53, 77) 87 (76, 100) Missing measurement, (%) 41 53 Urine Protein Trace or 1+ 13 8 8 Proteinuing present at 2+, 0.7 0.2 Proteinuing present at 3+, 0.7 0.2 9 14 14 16 Disatole Blood pressure mm/Hg, median (IQR) 42 (20) 38 9 33 (12, 73, 74) Missing measurement, (%) 44 0.3 Missing measurement, (%) 42 38 9 33 (12, 73, 74) Missing measurement, (%) 6 2 33 (12, 73, 74) Basing measurement, (%) 6 2 33 (12, 73, 74) Missing measurement, (%) 6 2 33 (12, 73, 74) Basing measurement, (%) 6 1 0.1 1 </td <td>HbA1c, % median (IQR)</td> <td>7.0 (6.3, 8.0)</td> <td>6.8 (6.2, 7.4)</td>	HbA1c, % median (IQR)	7.0 (6.3, 8.0)	6.8 (6.2, 7.4)		
Low Density Lipoprotein mg/dL, median (IQR) 93 (74, 118) 100 (80, 124) Missing measurement, (%) 40 20 Creatinine mg/dL, median (IQR) 1.2 (1.0, 1.4) 1.0 (0.9, 1.1) Glomerular filtration rate minim, median (IQR) 62 (53, 77) 87 (76, 100) Missing measurement, (%) 24 10 Proteinuria, (%) negative 41 53 Proteinuria present at 2+, 3 0.9 Proteinuria present at 3+, 0.7 0.2 Proteinuria present at 3+, 0.7 0.2 Systolic Blood pressure mm/fb, median (IQR) 136 (122,150) 134 (124,144) Diastolic Blood pressure mm/fb, median (IQR) 27 (25,0,31.2) 33.1 (29,7,37.4) Missing measurement, (%) 4 4 0.3 Missing measurement, %) 9 4 0.3 Missing measurement, %) 6 2 2 Masing measurement, %) 6 1 0.3 Missing measurement, %) 6 1 0.3 Missing measurement, %) 9 4 0.3	Missing measurement, (%)	25	`17 [`]		
Massing measurement, (%) 40 20 Creatinine mg/dL, median (IQR) 1.2 (10, 1.4) 1.0 (0.9, 1.1) Giomerular filtration rate m/min, median (IQR) 62 (53, 77) 87 (76, 100) Missing measurement, (%) 24 10 Proteinuria (%) negative 41 53 Urine Protein Trace or 1+ 13 8 Proteinurin present at 2+, 0.7 0.2 Proteinurin present at 3+, 0.7 0.2 Distoine Blood pressure mm/Hg, median (IQR) 126 (122, 150) 134 (124, 144) Distoine Blood pressure mm/Hg, median (IQR) 12 (3 (25, 0, 31.2) 33 (128, 7, 7.4) Missing measurement, (%) 6 2 2 Body Mass Index (Kg/meter/), median (IQR) 27 9 (25, 0, 31.2) 33 (128, 7, 7.4) Maignancy 9 4 0.3 Liver respiratory failure 1 0.1 Congestive heart failure 27 1 1 Cardiovascular disease 6 1 Maignancy 9 4 1 Liver (respirotaly failure 1 0.3<	Low Density Lipoprotein mg/dL, median (IQR)	93 (74, 118)	100 (80, 124)		
Creatinine mg/dL, median (IOR) 1.2 (1.0, 1.4) 1.0 (0.9, 1.1) Giomerular filtration rate multinin, median (IOR) 62 (53, 77) 87 (76, 100) Missing measurement, (%) 24 10 Proteinuria, (%) 24 13 Urine Protein Trace or 1+ 13 8 Proteinuria present at 2+, 3 0.9 Proteinuria present at 2+, 0.7 0.2 Proteinuria present at 3+, 0.7 0.2 Systelle Blood pressure mm/Hg, median (IQR) 126 (122, 150) 134 (124, 144) Diastolic Blood pressure mm/Hg, median (IQR) 27.9 (25.0, 31.2) 33.1 (29, 7.37.4) Missing measurement, (%) 4 0.3 1.4 Body Mass Index (kymeter'), median (IQR) 27.9 (25.0, 31.2) 33.1 (29, 7.37.4) Malignancy 9 4 0.3 Liver (respiratory failure 4 0.3 1 HV 1 0.1 1 1 Cardiovascular disease 41 1 1 Serious mental illnes 15 18 1	Missing measurement, (%)	40	20		
Giomerular filtration rate ml/min, median (IQR) 62 (53, 77) 87 (76, 100) Missing measurement, (%) 24 10 Proteinuria, (%) negative 41 53 Urine Proteinuria present at 2+, 3 0.9 Proteinuria present at 3+, 0.7 0.2 Proteinuria present at 4+, 0.1 0 Missing measurement, (%) 42 38 Diatobic Blood pressure mm/Hg, median (IQR) 126 (122,150) 134 (124,144) Diatobic Blood pressure mm/Hg, median (IQR) 72 (64, 80) 78 (70, 84) Missing measurement, (%) 6 2 33.1 (29,737.4) Body Mass Index (kymeter), median (IQR) 27.9 (25, 0.31.2) 33.1 (29,737.4) Malignancy 9 4 1 Body Mass Index (kymeter), median (IQR) 27.9 (25, 0.31.2) 33.1 (29,737.4) Malignancy 9 4 1 1 Body Mass Index (kymeter), median (IQR) 1 0.1 1 1 Cangetive heart failure 1 0.1 1 1 1 Carlica valve disease	Creatinine mg/dL, median (IQR)	1.2 (1.0, 1.4)	1.0 (0.9, 1.1)		
Massing measurement, (%) 24 10 Proteinuria, (%) 41 53 Urine Protein Trace or 1+ 13 8 Proteinuria present at 2+, 3 0.9 Proteinuria present at 3+, 0.7 0.2 Proteinuria present at 3+, 0.7 0.2 Systolic Blood pressure mm/Hg, median (IQR) 42 38 Systolic Blood pressure mm/Hg, median (IQR) 72 (64, 80) 78 (70, 84) Massing measurement, (%) 4 1 Body Mass Index (kymeter), median (IQR) 27.9 (25, 0, 31.2) 33.1 (29, 737.4) Massing measurement, (%) 6 2 Baseline Co-morbidities(%)‡ 9 4 Liver/ respiratory failure 4 0.3 HV 1 0.1 Cardiovascular disease 15 18 Smoking 10 12 Chronic Obstructive Pulmonary Disease 23 4 Partinon's 1 0.3 Partinon's 12 26 2002-03 201 12 <	Glomerular filtration rate ml/min, median (IQR)	62 (53, 77)	87 (76, 100)		
Proteinuria (vs) negative 41 53 Unne Proteinuria present at 2+, 3 0.9 Proteinuria present at 3+, 0.7 0.2 Proteinuria present at 3+, 0.1 0 Missing measurement, (%) 42 38 Distolic Blood pressure mm/Hg, median (IQR) 136 (122,150) 134 (124,144) Distolic Blood pressure mm/Hg, median (IQR) 2 (64, 80) 78 (70, 84) Missing measurement, (%) 2 3.3.1 (29,737.4) Missing measurement, (%) 27.9 (25, 0, 31.2) 3.3.1 (29,7,37.4) Missing measurement, (%) 2 3 4 Congestive heart failure 27 1 0.1 Congestive heart failure 27 1 1 Cardiovascular disease 10 12 2 Chronic Obstructive Pulmonary Disease 1 0.3 4 Parkinson's 1 0.3 4 Parkinson's 1 0.3 2 Chronic Obstructive Pulmonary Disease 6 1 1 Cardiac valve disease <td>Missing measurement, (%)</td> <td>24</td> <td>10</td>	Missing measurement, (%)	24	10		
Unine Protein Ingreson 42+, Proteinung present at 3+, 1,3 8 Proteinung present at 3+, 0,7 0,2 Proteinung present at 3+, 0,1 0 Missing measurement, (%) 42 38 Systolic Blood pressure mm/Hg, median (IQR) 126 (122,150) 134 (124,144) Diastolic Blood pressure mm/Hg, median (IQR) 27.9 (25.0, 31.2) 33.1 (29.7, 37.4) Missing measurement, (%) 4 1 1 Body Mass Index (kg/meter ¹), median (IQR) 27.9 (25.0, 31.2) 33.1 (29.7, 37.4) Missing measurement, (%) 9 4 1 Malignancy 9 4 1 Liver (respiratory failure 1 0,1 1 Congesive heart failure 27.7 1 1 Cardioxacular disease 15 18 1 Smoking 10 12 1 Quo2-03 10 1 0.3 Year N(%) 22 15 20 Quo2-03 10 1 0.3 Quo2-03 22	Proteinuria, (%) negative	41	53		
Proteinuna present at 3+, 0.7 0.2 Proteinuna present at 4+ 0.1 0 Missing measurement, (%) 42 38 Systolic Blood pressure mm/Hg, median (IQR) 136 (122,150) 134 (124,144) Disatolic Blood pressure mm/Hg, median (IQR) 72 (64, 80) 78 (70, 84) Missing measurement, (%) 4 1 6 Body Mass Index (kg/meter), median (IQR) 27.9 (25, 0, 31.2) 33.1 (29, 7.37.4) Missing measurement, (%) 6 2 Baseline Co-morbidities(%)‡ 6 2 Malignancy 9 4 1 Liver/ respiratory failure 4 0.3 1 HIV 1 0.1 1 1 Cardiaz valve disease 10 12 1 1 Chronic Obstructive Pulmonary Disease 23 4 1 Z002-03 40 11 204 206 2006 12 26 200 200 200 200 200 200 200 200 2	Urine Protein Trace or 1+	13	8		
Proteinuing present at S*, 0.7 0.2 Proteinuing present at S*, 0.1 0 Missing measurement, (%) 42 38 Systolic Blood pressure mm/Hg, median (IQR) 72 (64, 80) 78 (70, 84) Missing measurement, (%) 4 1 Body Mass Index (kg/meter), median (IQR) 27.9 (25.0, 31.2) 33.1 (29.7.37.4) Malignancy 9 4 2 Liver/ respiratory failure 4 0.3 1 Congestive heart failure 27.9 (25.0, 31.2) 33.1 (29.7.37.4) Malignancy 9 4 1 Liver/ respiratory failure 4 0.3 1 Congestive heart failure 27 1 1 Cardiovascular disease 10 12 2 Chronic Obstructive Pulmonary Disease 22 10 2 Cardiac valve disease 6 1 3 Arrythmia 23 4 2 Vaer N(%) 2 2 2 2004 22 15	Proteinuna present at 2+,	3	0.9		
Channel (%) Ch O <tho< th=""> <tho< th=""> O <tho< td=""><td>Proteinuria present at 4</td><td>0.7</td><td>0.2</td></tho<></tho<></tho<>	Proteinuria present at 4	0.7	0.2		
Systolic Blood pressure mm/Hg, median (IQR) 136 (122,150) 134 (124,144) Diastolic Blood pressure mm/Hg, median (IQR) 72 (64, 80) 78 (70, 84) Missing measurement, (%) 4 1 Body Mass Index (kg/meter), median (IQR) 27.9 (25.0, 31.2) 33.1 (29,7,37.4) Missing measurement, (%) 6 2 Baseline Co-morbidities (%)‡ 6 2 Malignancy 9 4 1 Liver/ respiratory failure 4 0.3 1 Congestive heart failure 27.7 1 1 Cardiovascular disease 10 12 1 Chronic Obstructive Pulmonary Disease 23 4 1 2002-03 40 11 0.3 1 2005 17 22 20 20 2007 6 20 20 20 20 2006 12 26 20 20 20 2007 6 20 20 20 20 20 20 20	Missing measurement (%)	42	38		
Distolic Blood pressure mm/Hg, media (IQR) 72 (64, 80) 73 (70, 84) Missing measurement, (%) 4 1 Dody Mass Index (kg/metr), median (IQR) 22 (64, 80) 73 (70, 84) Maissing measurement, (%) 4 1 Baseline Co-morbidities(%)‡ 6 2 Maignancy 9 4 Liver/ respiratory failure 4 0.3 HIV 1 0.1 Cangestive heart failure 27 1 Cardioxscular disease 41 18 Serious mental liness 15 18 Smoking 10 12 Chronic Obstructive Pulmonary Disease 22 1 2002-03 40 11 2004 22 15 2005 17 22 2006 20 20 2008-2011 † 3 6 Use of Medications N (%) 7 8 Angiotensin Converting Enzyme Inhibitors 55 53 Angiotensin Converting Enzyme Inhibitors 39 </td <td>Systolic Blood pressure mm/Ha. median (IOR)</td> <td>136 (122 150)</td> <td>134 (124 144)</td>	Systolic Blood pressure mm/Ha. median (IOR)	136 (122 150)	134 (124 144)		
Missing measurement, (%) 14 1 Body Mass Index (kg/meter ²), median (IQR) 27.9 (25.0, 31.2) 33.1 (29.7, 37.4) Missing measurement, (%) 6 2 Baseline Co-morbidities(%); 9 4 Maignancy 9 4 Liver/ respiratory failure 4 0.3 HIV 1 0.1 Congestive heart failure 27 1 Cardiovascular disease 41 18 Serious mental illness 15 18 Smoking 10 12 Chronic Obstructive Pulmonary Disease 6 1 2002-03 40 11 2004 22 15 2005 17 22 2006 20 200 2007 6 20 2008-2011 † 3 6 Use of Medications N (%) 35 37 Angiotensin Converting Enzyme Inhibitors 55 53 Angiotensin I Receptor Blockers 19 13	Diastolic Blood pressure mm/Hg, median (IQR)	72 (64, 80)	78 (70, 84)		
Body Mass Index (kg/meter), median (IQR) 27.9 (25.0, 31.2) 33.1 (29.7,37.4) Missing measurement, (%) 6 2 Baseline Co-morbidities(%) † 9 4 Malignancy 9 4 Liver/respiratory failure 4 0.3 HIV 1 0.1 Congestive heart failure 27 1 Cardiovascular disease 41 18 Serious mental illness 15 18 Smoking 10 12 Chronic Obstructive Pulmonary Disease 23 4 Cardiac valve disease 6 1 Arrhythmia 23 4 Parkinson's 1 0.3 Year N (%) 2 15 2004 22 15 2005 17 22 2006 12 26 2007 6 20 2008-2011 † 3 6 Angiotensin I Receptor Blockers 55 53 Statin lipid lowering medications	Missing measurement. (%)	4	1		
Missing measurement, (%) 6 2 Baseline Co-morbidities(%)‡ 9 4 Malignancy 9 4 Liver/ respiratory failure 4 0.3 HIV 1 0.1 Congestive heart failure 27 1 Cardiovascular disease 41 18 Serious mental illness 15 18 Smoking 10 12 Chronic Obstructive Pulmonary Disease 6 1 Arrhythmia 23 4 Parkinson's 1 0.3 2004 22 15 2005 17 22 2006 12 26 2007 6 20 2008-2011 † 3 6 Use of Medications N (%) 13 13 Loop Diuretics 7 8 Doi Diatesin Converting Enzyme Inhibitors 55 53 Angiotensin Converting Enzyme Inhibitors 55 53 Angiotensin Channel Blockers 19 <td>Body Mass Index (kg/meter²), median (IQR)</td> <td>27.9 (25.0, 31.2)</td> <td>33.1 (29.7,37.4)</td>	Body Mass Index (kg/meter ²), median (IQR)	27.9 (25.0, 31.2)	33.1 (29.7,37.4)		
Baseline Co-morbidities(%)‡ 9 4 Malignancy 9 4 Liver/respiratory failure 4 0.3 HIV 1 0.1 Congestive heart failure 27 1 Cardiovascular disease 41 18 Serious mental illness 15 18 Smoking 10 12 Chronic Obstructive Pulmonary Disease 6 1 Cardiac valve disease 6 1 Arrhythmia 23 4 Parkinson's 1 0.3 Year N (%) 1 0.3 2002-03 40 11 2004 22 15 2005 17 26 2006 12 26 2007 6 20 2008-2011 † 3 6 Use of Medications N (%) 3 6 Angiotensin II Receptor Blockers 5 53 Carcium Channel Blockers 19 13 Lo	Missing measurement, (%)	6	2		
Mailgnancy 9 4 Liver/respiratory failure 4 0.3 HIV 1 0.1 Congestive heart failure 27 1 Cardiovascular disease 41 18 Serious mental illness 15 18 Smoking 10 12 Chronic Obstructive Pulmonary Disease 22 10 Cardiac valve disease 6 1 Arrhythmia 23 4 Parkinson's 1 0.3 2002-03 40 11 2004 22 15 2005 17 22 2006 12 26 2007 6 20 2008-2011 † 3 6 Use of Medications N (%)	Baseline Co-morbidities(%)‡				
Liver/ respiratory failure 4 0.3 HIV 1 0.1 Congestive heart failure 27 1 Cardiovascular disease 41 18 Serious mental illness 15 18 Smoking 10 12 Chronic Obstructive Pulmonary Disease 22 10 Cardiac valve disease 6 1 Arrhythmia 23 4 Parkinson's 1 0.3 2002-03 40 11 2004 22 15 2005 17 22 2006 20 20 2007 6 20 2008-2011 † 3 6 Use of Medications N (%)	Malignancy	9	4		
HIV 1 0.1 Corgestive heart failure 27 1 Cardiovascular disease 41 18 Serious mental illness 15 18 Smoking 10 12 Chronic Obstructive Pulmonary Disease 22 10 Cardiac valve disease 6 1 Arrhythmia 23 4 Parkinson's 1 0.3 Year N (%) 2002-03 40 11 2004 22 15 2005 17 22 2006 12 26 2007 6 20 2008-2011 † 3 6 Use of Medications N (%) 4 4 Angiotensin Converting Enzyme Inhibitors 55 53 Angiotensin Converting Enzyme Inhibitors 30 22 Thizide and potassium sparing diuretics 30 35 Non Selective alpha Blockers 19 13 Loop Diuretics 39 6 Other Anti hypertensive medications 15 4 Nitrates 24<	Liver/ respiratory failure	4	0.3		
Congestive heart failure 2/ 1 Cardiovascular disease 41 18 Serious mental illness 15 18 Smoking 10 12 Chronic Obstructive Pulmonary Disease 22 10 Cardiac valve disease 6 1 Arrhythmia 23 4 Parkinson's 1 0.3 Year N (%)	HIV	1	0.1		
Catabovascular bisease 41 16 Serious mental illness 15 18 Smoking 10 12 Chronic Obstructive Pulmonary Disease 22 10 Cardiac valve disease 6 1 Arrhythmia 23 4 Parkinson's 1 0.3 Year N (%) 2002-03 40 2004 22 15 2005 17 22 2006 12 26 2007 6 20 2008-2011 † 3 6 Use of Medications N (%) 3 6 Use of Medications N (%) 3 6 Cardium Channel Blockers 55 53 Angiotensin Converting Enzyme Inhibitors 35 30 Angiotensin Converting Enzyme Inhibitors 32 6 Cardium Channel Blockers 19 13 Loop Diuretics 30 35 Non Selective alpha Blockers 28 22 Statin Lipid lowering medic	Congestive heart failure	27	1		
Sendus Internal Infress 15 16 Smoking 10 12 Chronic Obstructive Pulmonary Disease 22 10 Cardiac valve disease 6 1 Arrhythmia 23 4 Parkinson's 1 0.3 Year N (%) 40 11 2002-03 40 11 2004 22 15 2005 12 26 2007 6 20 2008-2011 † 3 6 Use of Medications N (%) 7 8 Beta Blockers 55 53 Calcium Channel Blockers 30 22 Thiazide and potassium sparing diuretics 30 35 Non Selective alpha Blockers 19 13 Loop Diuretics 39 6 Other Anti hypertensive medications 28 22 Statin Lipid lowering medications 10 20 Anti-arrhythmics, digoxin and inotropes 5 1 Antit-arrhythmics,		41	18		
Shinking 10 12 Chronic Obstructive Pulmonary Disease 6 1 Cardiac valve disease 6 1 Arrhythmia 23 4 Parkinson's 1 0.3 2002-03 40 11 2004 22 15 2005 17 22 2006 20 20 2007 6 20 2008-2011 † 3 6 Use of Medications N (%) 7 8 Angiotensin Converting Enzyme Inhibitors 55 53 Angiotensin Converting Enzyme Inhibitors 30 22 Angiotensin Converting Enzyme Inhibitors 33 6 Angiotensin Converting Enzyme Inhibitors 33 6 Calcium Channel Blockers 7 8 Beta Blockers 30 35 Non Selective alpha Blockers 19 13 Loop Diuretics 39 6 Other Anti hypertensive medications 49 69 No	Senous mental liness	15	10		
Cardiac value disease 22 10 Cardiac value disease 6 1 Arrhythmia 23 4 Parkinson's 1 0.3 2002-03 40 11 2004 22 15 2005 17 22 2006 12 26 2007 6 20 2008-2011 † 3 6 Use of Medications N (%) 7 8 Angiotensin I Receptor Blockers 55 53 Angiotensin I Receptor Blockers 52 37 Calcium Channel Blockers 30 22 Thiazide and potassium sparing diuretics 30 35 Non Selective alpha Blockers 19 13 Loop Diuretics 39 6 Other Anti hypertensive medications 28 22 Statin lipid lowering medications 10 20 Non Statin Lipid lowering medications 15 4 Nitrates 24 9 Aspirini	Chronic Obstructive Pulmonary Disease	22	12		
Arthythmia 23 4 Parkinson's 1 0.3 Year N (%) 2002-03 40 11 2004 22 15 2005 17 22 2006 12 26 2007 6 20 2008-2011 † 3 6 Use of Medications N (%) 7 8 Angiotensin Converting Enzyme Inhibitors 55 53 Angiotensin I Receptor Blockers 7 8 Beta Blockers 52 37 Calcium Channel Blockers 30 22 Thiazide and potassium sparing diuretics 30 35 Non Selective alpha Blockers 19 13 Loop Diuretics 39 6 Other Anti hypertensive medications 28 22 Statin lipid lowering medications 15 4 Nitrates 24 9 Aspirin 21 17 Anticacyulants, platelet inhibitors 16 9 Oral Gluccoorticoids 16 9 Oral Gluccoorticoids <	Cardiac valve disease	6	1		
Parkinson's 1 0.3 Year N (%) 7 0.3 2002-03 40 11 2004 22 15 2005 17 22 2006 12 26 2007 6 20 2008-2011 † 3 6 Use of Medications N (%) Angiotensin Converting Enzyme Inhibitors 55 53 Angiotensin Converting Enzyme Inhibitors 55 53 Angiotensin V(%) 7 8 Beta Blockers 52 37 Calcium Channel Blockers 7 8 Beta Blockers 30 22 Thiazide and potassium sparing diuretics 30 35 Non Selective alpha Blockers 19 13 Loop Diuretics 39 6 Other Anti hypertensive medications 28 22 Statin lipid lowering medications 10 20 Non Stain Lipid lowering medications 15 4 Nitrates 24 9 Aspirin 21 17	Arrhythmia	23	4		
Year N (%) 40 11 2002-03 40 11 2004 22 15 2005 17 22 2006 12 26 2007 6 20 2008-2011 † 3 6 Use of Medications N (%) Angiotensin II Receptor Blockers 7 8 Beta Blockers 52 37 Calcium Channel Blockers 30 22 Thiazide and potassium sparing diuretics 30 35 Non Selective alpha Blockers 19 13 Loop Diuretics 39 6 Other Anti hypertensive medications 28 22 Statin lipid lowering medications 49 69 Non Stain Lipid lowering medications 10 20 Anti-arrhythmics, digoxin and inotropes 5 1 Anti-coagulants, platelet inhibitors 15 4 Nitrates 24 9 Aspirin 21 17 Anticocogulants, platelet inhibitors 16 9 Indicators of heath care utilization N	Parkinson's	1	0.3		
2002-03 40 11 2004 22 15 2005 17 22 2006 12 26 2007 6 20 2008-2011 † 3 6 Use of Medications N (%) Angiotensin Converting Enzyme Inhibitors 55 53 Angiotensin Converting Enzyme Inhibitors 52 37 Calcium Channel Blockers 30 22 Thiazide and potassium sparing diuretics 30 35 Non Stein Lipid Iowering medications 28 22 Statin lipid Iowering medications 10 20 Anticoagulants, platelet inhibitors 15 4<	Year N (%)				
20042215200517222006122620076202008-2011 †36Use of Medications N (%)Angiotensin Converting Enzyme Inhibitors5553Angiotensin II Receptor Blockers78Beta Blockers5237Calcium Channel Blockers3022Thiazide and potassium sparing diuretics3035Non Selective alpha Blockers1913Loop Diuretics396Other Anti hypertensive medications4969Non Stain Lipid lowering medications1020Anti-arrhythmics, digoxin and inotropes51Anticoagulants, platelet inhibitors154Nitrates249Aspirin2117Antipsychotics68Oral Glucocorticoids169Hospitalized in last year (Veterans Health)145Hospitalized within 30 days (Veterans Health)72Hospitalized within 30 days (Medicare/Medicaid)70.5	2002-03	40	11		
200517222006122620076202008-2011 †36Use of Medications N (%)Angiotensin Converting Enzyme Inhibitors5553Angiotensin II Receptor Blockers78Beta Blockers5237Calcium Channel Blockers3022Thiazide and potassium sparing diuretics3035Non Selective alpha Blockers1913Loop Diuretics396Other Anti hypertensive medications2822Statin Lipid lowering medications4969Non Stain Lipid lowering medications1020Anti-arrhythmics, digoxin and inotropes51Anticoagulants, platelet inhibitors154Nitrates249Aspirin2117Antipsychotics68Oral Gluccorticoids169Indicators of health care utilization N (%)145Hospitalized in last year (Wedicare/Medicaid)243Hospitalized within 30 days (Wedicare/Medicaid)70.5	2004	22	15		
2006122620076202008-2011 †36Use of Medications N (%)Angiotensin Converting Enzyme Inhibitors5553Angiotensin II Receptor Blockers78Beta Blockers5237Calcium Channel Blockers3022Thiazide and potassium sparing diuretics3035Non Selective alpha Blockers1913Loop Diuretics396Other Anti hypertensive medications2822Statin lipid lowering medications1020Anti-arrhythmics, digoxin and inotropes51Anticoagulants, platelet inhibitors154Nitrates249Aspirin2117Antipsychotics68Oral Glucocorticoids169Indicators of health care utilization N (%)145Hospitalized in last year (Veterans Health)145Hospitalized within 30 days (Veterans Health)70.5	2005	17	22		
20076202008-2011 †36Use of Medications N (%)Angiotensin Converting Enzyme Inhibitors5553Angiotensin II Receptor Blockers78Beta Blockers5237Calcium Channel Blockers3022Thiazide and potassium sparing diuretics3035Non Selective alpha Blockers1913Loop Diuretics396Other Anti hypertensive medications2822Statin lipid lowering medications4969Non Stain Lipid lowering medications1020Anticoagulants, platelet inhibitors154Nitrates249Aspirin2117Antipsychotics68Oral Glucocorticoids169Indicators of health care utilization N (%)145Hospitalized in last year (Medicare/Medicaid)243Hospitalized within 30 days (Veterans Health)70.5	2006	12	26		
2008-2011 T36Use of Medications N (%)	2007	6	20		
Ose of interactions N (%)5553Angiotensin Converting Enzyme Inhibitors5553Angiotensin II Receptor Blockers78Beta Blockers5237Calcium Channel Blockers3022Thiazide and potassium sparing diuretics3035Non Selective alpha Blockers1913Loop Diuretics396Other Anti hypertensive medications2822Statin lipid lowering medications4969Non Stain Lipid lowering medications1020Anti-arrhythmics, digoxin and inotropes51Anticoagulants, platelet inhibitors154Nitrates249Aspirin2117Antipsychotics68Oral Glucocorticoids169Indicators of health care utilization N (%)145Hospitalized in last year (Veterans Health)145Hospitalized within 30 days (Veterans Health)72Hospitalized within 30 days (Veterans Health)70.5	2008-2011 T	3	6		
Angiotensin Conventing Enzyme minitors3335Angiotensin II Receptor Blockers78Beta Blockers5237Calcium Channel Blockers3022Thiazide and potassium sparing diuretics3035Non Selective alpha Blockers1913Loop Diuretics396Other Anti hypertensive medications2822Statin lipid lowering medications4969Non Stain Lipid lowering medications1020Anti-arrhythmics, digoxin and inotropes51Anticoagulants, platelet inhibitors154Nitrates249Aspirin2117Antipsychotics68Oral Glucocorticoids169Hospitalized in last year (Veterans Health)145Hospitalized within 30 days (Veterans Health)72Hospitalized within 30 days (Veterans Health)70.5	Angiotensin Converting Enzyme Inhibitors	55	53		
IngredictionI0Beta Blockers5237Calcium Channel Blockers3035Non Selective alpha Blockers1913Loop Diuretics396Other Anti hypertensive medications2822Statin lipid lowering medications4969Non Stain Lipid lowering medications1020Anti-arrhythmics, digoxin and inotropes51Anticoagulants, platelet inhibitors154Nitrates249Aspirin2117Antipsychotics68Oral Glucocorticoids169Indicators of health care utilization N (%)145Hospitalized in last year (Veterans Health)72Hospitalized within 30 days (Veterans Health)70Hospitalized within 30 days (Medicare/Medicaid)70	Angiotensin Converting Enzyme minibitors	7	8		
Calcium Channel Blockers3022Thiazide and potassium sparing diuretics3035Non Selective alpha Blockers1913Loop Diuretics396Other Anti hypertensive medications2822Statin lipid lowering medications4969Non Stain Lipid lowering medications1020Anti-arrhythmics, digoxin and inotropes51Anticoagulants, platelet inhibitors154Nitrates249Aspirin2117Antipsychotics68Oral Glucocorticoids169Indicators of health care utilization N (%)145Hospitalized in last year (Medicare/Medicaid)243Hospitalized within 30 days (Veterans Health)72Hospitalized within 30 days (Medicare/Medicaid)70.5	Beta Blockers	52	37		
Thiazide and potassium sparing diuretics3035Non Selective alpha Blockers1913Loop Diuretics396Other Anti hypertensive medications2822Statin lipid lowering medications4969Non Stain Lipid lowering medications1020Anti-arrhythmics, digoxin and inotropes51Anticoagulants, platelet inhibitors154Nitrates249Aspirin2117Antipsychotics68Oral Glucocorticoids169Indicators of health care utilization N (%)145Hospitalized in last year (Veterans Health)145Hospitalized within 30 days (Veterans Health)72Hospitalized within 30 days (Medicare/Medicaid)70.5	Calcium Channel Blockers	30	22		
Non Selective alpha Blockers1913Loop Diuretics396Other Anti hypertensive medications2822Statin lipid lowering medications4969Non Stain Lipid lowering medications1020Anti-arrhythmics, digoxin and inotropes51Anticoagulants, platelet inhibitors154Nitrates249Aspirin2117Antipsychotics68Oral Glucocorticoids169Indicators of health care utilization N (%)145Hospitalized in last year (Medicare/Medicaid)243Hospitalized within 30 days (Veterans Health)72Hospitalized within 30 days (Medicare/Medicaid)70.5	Thiazide and potassium sparing diuretics	30	35		
Loop Diuretics396Other Anti hypertensive medications2822Statin lipid lowering medications4969Non Stain Lipid lowering medications1020Anti-arrhythmics, digoxin and inotropes51Anticoagulants, platelet inhibitors154Nitrates249Aspirin2117Antipsychotics68Oral Glucocorticoids169Indicators of health care utilization N (%)145Hospitalized in last year (Veterans Health)145Hospitalized within 30 days (Veterans Health)72Hospitalized within 30 days (Medicare/Medicaid)70.5	Non Selective alpha Blockers	19	13		
Other Anti hypertensive medications2822Statin lipid lowering medications4969Non Stain Lipid lowering medications1020Anti-arrhythmics, digoxin and inotropes51Anticoagulants, platelet inhibitors154Nitrates249Aspirin2117Antipsychotics68Oral Glucocorticoids169Indicators of health care utilization N (%)145Hospitalized in last year (Veterans Health)145Hospitalized within 30 days (Veterans Health)72Hospitalized within 30 days (Medicare/Medicaid)70.5	Loop Diuretics	39	6		
Statin lipid lowering medications4969Non Stain Lipid lowering medications1020Anti-arrhythmics, digoxin and inotropes51Anticoagulants, platelet inhibitors154Nitrates249Aspirin2117Antipsychotics68Oral Glucocorticoids169Indicators of health care utilization N (%)145Hospitalized in last year (Veterans Health)145Hospitalized within 30 days (Veterans Health)72Hospitalized within 30 days (Medicare/Medicaid)70.5	Other Anti hypertensive medications	28	22		
Non Stain Lipid lowering medications1020Anti-arrhythmics, digoxin and inotropes51Anticoagulants, platelet inhibitors154Nitrates249Aspirin2117Antipsychotics68Oral Glucocorticoids169Indicators of health care utilization N (%)145Hospitalized in last year (Veterans Health)145Hospitalized within 30 days (Veterans Health)72Hospitalized within 30 days (Medicare/Medicaid)70.5	Statin lipid lowering medications	49	69		
Anti-armythmics, digoxin and inotropes51Anticoagulants, platelet inhibitors154Nitrates249Aspirin2117Antipsychotics68Oral Glucocorticoids169Indicators of health care utilization N (%)145Hospitalized in last year (Veterans Health)145Hospitalized within 30 days (Veterans Health)72Hospitalized within 30 days (Medicare/Medicaid)70.5	Non Stain Lipid lowering medications	10	20		
Anticoagulants, platelet infibitors154Nitrates249Aspirin2117Antipsychotics68Oral Glucocorticoids169Indicators of health care utilization N (%)145Hospitalized in last year (Veterans Health)145Hospitalized within 30 days (Veterans Health)72Hospitalized within 30 days (Medicare/Medicaid)70.5	Anti-arrnythmics, digoxin and inotropes	5	1		
Nutrates249Aspirin2117Antipsychotics68Oral Glucocorticoids169Indicators of health care utilization N (%)145Hospitalized in last year (Veterans Health)145Hospitalized within 30 days (Veterans Health)72Hospitalized within 30 days (Medicare/Medicaid)70.5	Anticoaguiants, platelet innibitors	15	4		
Antipsychotics 6 8 Oral Glucocorticoids 16 9 Indicators of health care utilization N (%) 16 9 Hospitalized in last year (Veterans Health) 14 5 Hospitalized within 30 days (Veterans Health) 7 2 Hospitalized within 30 days (Medicare/Medicaid) 7 0.5	Ivillales Aspirin	24	9 17		
Oral Glucocorticoids 0 0 Indicators of health care utilization N (%) 16 9 Hospitalized in last year (Veterans Health) 14 5 Hospitalized within 30 days (Veterans Health) 24 3 Hospitalized within 30 days (Veterans Health) 7 2 Hospitalized within 30 days (Medicare/Medicaid) 7 0.5	Antinevenotice	21 6	ι <i>ι</i> Ω		
Indicators of health care utilization N (%) 10 5 Hospitalized in last year (Veterans Health) 14 5 Hospitalized in last year (Medicare/Medicaid) 24 3 Hospitalized within 30 days (Veterans Health) 7 2 Hospitalized within 30 days (Medicare/Medicaid) 7 0.5	Oral Glucocorticoids	16	o Q		
Hospitalized in last year (Veterans Health)145Hospitalized in last year (Medicare/Medicaid)243Hospitalized within 30 days (Veterans Health)72Hospitalized within 30 days (Medicare/Medicaid)70.5	Indicators of health care utilization N (%)	10	3		
Hospitalized in last year (Medicare/Medicaid)243Hospitalized within 30 days (Veterans Health)72Hospitalized within 30 days (Medicare/Medicaid)70.5	Hospitalized in last year (Veterans Health)	14	5		
Hospitalized within 30 days (Veterans Health) 7 2 Hospitalized within 30 days (Medicare/Medicaid) 7 0.5	Hospitalized in last year (Medicare/Medicaid)	24	3		
Hospitalized within 30 days (Medicare/Medicaid) 7 05	Hospitalized within 30 days (Veterans Health)	7	2		
	Hospitalized within 30 days (Medicare/Medicaid)	7	0.5		

Nursing Home encounter in last year	0.1	0.03
Outpatient Visits in past year	6 (3, 10)	5 (3, 8)
Number Medications	11 (8,16)	9 (6, 14)
Medicare use in last year	48	20
Medicaid use in last year	29	5

Table S4. Description and Characteristics of the weighted analysis cohort

The weighted analyses were performed using inverse probability of treatment weights (IPTW). As opposed to a matched analysis which balances the baseline covariate distributions by selecting a subset of patients from each exposure, a weighted analysis balances the covariate distributions by assigning various weights to the patients in one exposure such that the weighted group now resembles the other group. When comparing metformin and sulfonylurea users, the sulfonylurea users were weighted so that their distribution of covariates resembled that of the metformin users. This was achieved by using stabilized IPTW such that metformin users receive a weight of 1 and sulfonylurea users a weight of ei/(1-ei), where e is the probability of patient i receiving metformin given their covariates. This creates a pseudo-cohort that uses all of the eligible patients. In simple terms, the older, less healthy sulfonylurea users (who are over-abundant relative to metformin) are down-weighted to match the metformin distribution and the younger, healthier sulfonyurea users are up-weighted to match the metformin population. The sum of the metformin users' weights will equal the number of metformin users because they each received a weight of 1. The sum of the sulfonylurea users' weights will approximate the number of metformin users because the sulfonylurea users are being weighted to approximate that group. The sum will not equal the number of metformin users exactly because the IPTW rely on modeling the exposure and thus provide an approximate solution. Like with matching, the success of the weighting in achieving a well-balanced pseudo-cohort can be seen in the table of patient characteristics and plot of standardized differences. Also like matching, the weighted analysis may be used with or without additional direct covariate adjustment. The analysis that does not use additional covariate adjustment estimates the average sulfonylurea versus metformin effect in a population of metformin users - our control group. This is referred to as the average treatment effect among controls (ATC). In the metformin versus thiazolidinedione comparison, the smaller thiazolidinedione group could not be easily up-weighted to approximate the much larger metformin group; however, the metformin group could be easily down-weighted to approximate the thiazolidinedione users. Hence, we used the thiazolidinedione users as the stabilizing population and estimated the average treatment effect among the treated population (ATT).

Characteristics	Weighted Cohort pr	imary exposure	Weighted Cohort with	Weighted Cohort with positive control	
	Sulfonylurea Weighted	Metformin	Metformin Weighted	Thiazolidinedione	
	N=125,362	N=126,867	N=6967	N=6945	
Age, median (IQR)	62 (56, 71)	62 (56, 71)	68 (59, 75)	67 (59, 75)	
Male (%)	95	95	97	97	
Race, (%)					
White	76	76	80	80	
Black	12	13	10	10	
Hispanic/ Other	4	4	7	7	
Missing	7	7	3	3	
HbA1c, % median (IQR)	6.9 (6.3, 7.6)	6.8 (6.3, 7.5)	6.6 (6.1, 7.3)	6.6 (6.0, 7.2)	
Missing measurement, (%)	19	19	35	34	
Low Density Lipoprotein mg/dL, median (IQR)	99 (79, 123)	99 (79, 123)	96 (77, 119)	97 (78, 121)	
Missing measurement, (%)	25	25	37	36	
Creatinine mg/dL, median (IQR)	1.0 (0.9, 1.1)	1.0 (0.9, 1.1)	1.10 (0.9, 1.20)	1.10 (0.9, 1.20)	
Glomerular filtration rate ml/min, median (IQR)	83.7 (71, 98)	83.7 (71, 99)	77 (64, 92)	76 (62, 91)	
Missing measurement, (%)	14	14	28	28	
Proteinuria, (%) negative	51	51	47	47	
Urine Protein Trace or 1+	10	10	8	8	
Proteinuria present at 2+,	1	1	1	1	
Proteinuria present at 3+,	0	0	0	0	
Proteinuria present at 4+	0	0	0	0	
Missing measurement, (%)	38	39	43	43	
Systolic Blood pressure mm/Hg, median (IQR)	135 (124,146)	135 (124, 146)	134 (123,145)	133 (122, 144) O	
Diastolic Blood pressure mm/Hg, median (IQR)	77 (70, 84)	77 (70, 84)	73 (66, 80)	73 (66, 80)	
Missing measurement, (%)	2	2	6	5	

Body Mass Index (kg/meter ²), median (IQR)	31.9 (28.5, 36.2)	32.0 (28.6, 36.2)	30.4 (27.2, 34.3)	30.5 (27.3, 34.0)
Missing measurement, (%)	3	3	7	6
Baseline Co-morbidities(%)‡				
Malignancy	5	5	6	6
Liver/ respiratory failure	1	1	1	1
HIV	0	0	0	0
Congestive heart failure	4	4	6	7
Cardiovascular disease	23	22	30	30
Serious mental illness	17	17	15	15
Smoking	12	12	8	8
Chronic Obstructive Pulmonary Disease	12	12	12	12
Cardiac valve disease	1	1	2	2
Arrhythmia	7	6	10	10
Parkinson's	1	0	1	1
Use of Medications N (%)				
Angiotensin Converting Enzyme Inhibitors	53	53	49	49
Angiotensin II Receptor Blockers	8	8	12	12
Beta Blockers	40	40	40	40
Calcium Channel Blockers	24	24	27	27
Thiazide and potassium sparing diuretics	32	33	28	28
Non Selective alpha Blockers	14	14	16	15
Loop Diuretics	10	10	16	16
Other Anti hypertensive medications	24	24	25	25
Statin Lipid lowering agents	64	64	64	64
Non Statin lipid Lowering agents	18	18	17	17
Anti-arrhythmics, digoxin and inotropes	2	1	3	2
Anticoagulants, platelet inhibitors	5	5	7	7
Nitrates	11	11	14	14
Aspirin	17	17	14	14
Antipsychotics	8	8	6	6
Oral Glucocorticoids	11	11	10	10
Indicators of health care utilization N (%)				
Hospitalized in last year (Veterans Health)	6	6	4	4
Hospitalized in last year (Medicare/Medicaid)	6	6	13	13
Hospitalized within 30 days (Veterans Health)	3	3	2	2
Hospitalized within 30 days (Medicare/ Medicaid)	1	1	2	2
Nursing Home encounter in last year	0	0	0	0
Outpatient Visits in past year	6 (3, 9)	6 (3, 9)	5 (3, 9)	5 (3, 9)
Number Medications	10 (7,14)	10 (7, 15)	10 (7, 14)	10 (7, 14)
Medicare use in last year	24	23	37	38
Medicaid use in last year	8	8	13	13

Table S5. Sensitivity Analyses evaluating the hazard of heart failure in first 180 days of use of Sulfonylurea versus Metformin and Thiazolidinedione versus Metformin, using new-user design and inverse probability treatment weighted analysis

Weighted Analysis	Metformin	Sulfonylurea Weighted*	Metformin Weighted*	Thiazolidinedione
N at risk†	166397	163995	10200	10164
Heart failure hospitalization or cardiovascular death	624	915.9	72.7	125
Person Years	80031.8	78299.2	4881.9	4872.4
Unadjusted Rate/1000 person-years	7.8 (7.2, 8.4)	11.7 (11.0, 12.5)	14.9 (11.9, 18.7)	25.7 (21.6, 30.6)
Adjusted Hazard Ratio (95% CI)	Reference	1.50 (1.35, 1.66)	Reference	1.72 (1.36, 2.18)
Heart failure emergency department visit, hospitalization or cardiovascular death	769	1138.3	88.7	141
Person Years	79994.7	78240.8	4877.3	4869.8
Unadjusted Rate/1000 person-years	9.6 (9.0, 10.3)	14.5 (13.7, 15.4)	18.2 (14.8, 22.3)	29 (24.6, 34.0)
Adjusted Hazard Ratio (95% CI)	Reference	1.51 (1.37, 1.66)	Reference	1.59 (1.28, 1.98)

*For the weighted analysis comparing sulfonylurea to metformin, the sulfonylurea population is weighted by their characteristics to more closely resemble the younger and healthier metformin population. For the weighted analysis comparing thiazolidinedione to metformin, the metformin population is weighted by their characteristics to more closely resemble the older population. Refer to Table S4 for details.

† The N at risk for the analysis of the first 180 days is larger then for the primary analysis cohort because it includes all patients from the primary unmatched cohort and also includes people who were excluded during the 180 day lag period for being non persistent; not having a full 180 days of follow-up; those who died; or were censored for reaching the threshold creatinine.

Table S6. Analysis of sensitivity to unmeasured confounding¹

We evaluated the risk of heart failure in the presence of an unobserved confounder with a relative hazard of 2.3 for heart failure risk, and various prevalence levels of the confounder by exposure group. The primary analysis yielded a greater risk of heart failure with sulfonylurea use over metformin use; HR (95% CI): 1.32 (1.21, 1.43). The bolded numbers correspond to the necessary differential prevalence of such a confounder between exposure groups that could account for study results being the result of such confounding.

		Prevalence of unmeasured confounder in metformin users								
		0.0	0.1	0.2	0.3	0.4	0.5			
ers	0	1.32	1.49	1.66	1.84	2.01	2.17			
	0	(1.21,1.43)	(1.37,1.62)	(1.53,1.80)	(1.68,1.99)	(1.84,2.17)	(2.00,2.36)			
red a us	0.1	1.17	1.32	1.47	1.62	1.78	1.93			
asu ureá	0.1	(1.07,1.27)	(1.21,1.43)	(1.35,1.60)	(1.49,1.76)	(1.63,1.92)	(1.77,2.09)			
o.2 nume	0.2	1.05	1.18	1.32	1.46	1.59	1.73			
	0.2	(0.96,1.14)	(1.09,1.28)	(1.21,1.43)	(1.34,1.58)	(1.46,1.73)	(1.59,1.87)			
in S	0.2	0.95	1.07	1.2	1.32	1.44	1.57			
aler	0.5	(0.87,1.03)	(0.98,1.16)	(1.10,1.30)	(1.21,1.43)	(1.32,1.56)	(1.44,1.70)			
Prev four	0.4	0.87	0.98	1.09	1.21	1.32	1.43			
iuo:	0.4	(0.80,0.94)	(0.90,1.06)	(1.00,1.19)	(1.11,1.31)	(1.21,1.43)	(1.31,1.55)			
	0.5	0.80	0.90	1.01	1.11	1.22	1.32			
	0.5	(0.73,0.87)	(0.83,0.98)	(0.92,1.09)	(1.02,1.21)	(1.12,1.32)	(1.21,1.43)			

The observed risk of prior heart failure history with the primary outcome was an HR of 2.3. For an unmeasured confounder of this strength to tip the primary finding of this paper into statistical non-significance, it would need to be independent of the observed covariates and 17% more prevalent among sulfonylurea users if the prevalence among metformin users was 0%. If the prevalence in metformin users was between 20-50%, it would need to be 21-27% **more** prevalent. If the prevalence in metformin users was 70%, an unmeasured confounder of this strength could not tip the analysis into statistical non-significance. Due to the heterogeneous prescribing practices in the VHA during the study period, selection bias of this degree was not observed. There were no differences in prevalence of this magnitude among the observed covariates in the full (pre-matching) cohort (Table 1).

Figure S1. Study Design Schematic

Below is an example patient who initiated Metformin after having 180 days free of any antidiabetic drug. Sulfonylurea and Thiazolidinedione person time are tracked in the same manner. **Main analysis:**

Persistent exposure required: Gaps (red bars) of up to 90 days are allowed in order to refill the regimen. Patients are censored at addition of another drug or no medication refills within 90 days. **Sensitivity analyses:**

Persistent exposure not required: In this approach patients are analyzed as users of their incident prescribed regimen regardless of switching, stopping or additions (akin to intent to treat analysis) **First 180 days:** This person time has a high likelihood of exposure misclassification and was excluded in above two analyses. This analysis of the first 180 days includes both those that do and don't refill their prescriptions as well as those who make other regimen changes, such as switching regimens and stopping medications. The resultant exposure misclassification, if non-differential would make it harder to show differences between treatment regimens.







Propensity Scores

Figure S3. Mean Standardized difference plot comparing metformin versus sulfonylurea



variable

Supplemental References:

1. Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. *Epidemiology*. 2005;16:17-24.

2. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivariate Behav Res.* 2011;46:399-424.

3. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. *Stat Med.* 2015;34:3661-79.